N6-methyladenosine (m6A) is a prevalent post-transcriptional modification of eukaryotic mRNA that influences RNA stability and translation. Dysregulation of m6A machinery has been linked to cancer biology. This study examined the function of the m6A-binding protein YTHDF2 in the pathogenesis of cutaneous melanoma, focusing on its potential role in regulating ferroptosis via control of HMOX1 expression.
Analyses of public cancer databases reported that YTHDF2 expression is elevated across a range of malignancies, including cutaneous melanoma. Within melanoma, YTHDF2 levels showed a positive correlation with PD-L1 expression and a negative correlation with measured immune and stromal scores, suggesting associations between YTHDF2 expression and the tumor immune microenvironment.
Functional experiments in melanoma cell models demonstrated that reducing YTHDF2 expression suppressed cell proliferation and increased the proportion of Annexin V/PI–positive cells, indicating increased cell death. Importantly, the increased cell death phenotype induced by YTHDF2 knockdown was rescued by application of a ferroptosis inhibitor, implicating ferroptosis as the dominant cell-death mechanism linked to YTHDF2 loss in these cells.
Molecular and biochemical assays following YTHDF2 depletion revealed multiple changes consistent with enhanced ferroptosis. These included increases in intracellular Fe2+, elevated malondialdehyde (an indicator of lipid peroxidation), increased reactive oxygen species, and higher levels of lipid peroxidation. Concurrently, glutathione-related protective effects were reduced. Each of these biochemical alterations was reversed when ferroptosis was pharmacologically inhibited, supporting a causal relationship between YTHDF2 loss and ferroptotic processes in melanoma cells.
Integrated transcriptomic approaches combining RNA sequencing (RNA-seq) and RNA immunoprecipitation sequencing (RIP-seq) were used to identify direct RNA targets of YTHDF2. These analyses indicated that YTHDF2 binds to m6A-modified regions on HMOX1 transcripts. The interaction was associated with reduced stability of HMOX1 mRNA and consequent downregulation of HMOX1 expression when YTHDF2 is present. By promoting destabilization of HMOX1 mRNA in an m6A-dependent manner, YTHDF2 was proposed to modulate intracellular pathways that control iron handling and lipid peroxidation, thereby regulating susceptibility to ferroptosis.
The study reports that metformin treatment inhibited expression of YTHDF2 in melanoma cells and concomitantly promoted ferroptosis. This observation suggests a potential pharmacologic route to modulate the m6A–YTHDF2–HMOX1 axis and enhance ferroptotic cell death in melanoma. The abstract does not provide dose, treatment duration, or detailed experimental parameters for metformin exposure; these details would require review of the full article.
In vivo experiments were performed and described as corroborating the regulatory role of YTHDF2 in ferroptosis and melanoma progression. The animal studies received approval from the Ethics Committee for Animal Studies at Central Hospital Affiliated to Shandong First Medical University. Specifics such as animal models used, sample sizes, tumor growth metrics, and statistical outcomes are not provided in the abstract and are available only in the full text.
The findings identify YTHDF2 as a modulator of ferroptosis in cutaneous melanoma through m6A-dependent regulation of HMOX1 mRNA stability. These data support the concept of targeting the m6A reader YTHDF2 or its downstream pathway as a therapeutic strategy to increase ferroptotic vulnerability in melanoma. The observed suppression of YTHDF2 by metformin highlights a candidate repurposing opportunity.
Limitations indicated by the abstract: the summary does not include experimental protocols, quantitative results, sample sizes, or potential off-target effects. It also does not report any clinical data. For mechanistic validation, dose–response relationships, safety assessments, and translational feasibility, readers should consult the full published article.
This work proposes that YTHDF2 drives malignant progression in cutaneous melanoma by binding m6A-modified HMOX1 transcripts and promoting their destabilization, thereby reducing HMOX1 expression and modulating ferroptosis susceptibility. The ability of metformin to downregulate YTHDF2 and promote ferroptosis provides a potential therapeutic angle. Further details and complete data are contained in the full text of the publication for readers seeking experimental specifics and quantitative outcomes.